Scholarlink

Objective <p>The objective of this study was to explore whether combined assessment of TgAb and TPOAb perform a higher predictive value to adverse pregnancy outcomes than isolated TPOAb during early pregnancy.</p> Methods <p>This was a retrospective study of 4678 pregnant women receiving prenatal care at Peking University First Hospital from October 2017 to August 2018. Demographic and clinical data, including thyroid hormone levels, were retrieved from electronic medical records. The general information and incidence of adverse pregnancy outcomes were compared between different subgroups of thyroid function and antibody status.</p> Results <p>In total, 2673 women were enrolled. 6.70% (179/2673) and 8.27% (221/2673) of the pregnant women were TPOAb positive and TgAb positive, respectively. The median thyroid-stimulating hormone (TSH) level was higher in the TPOAb or TgAb positive group than in the antibody-negative group [1.40 (0.96, 2.01) <i>vs</i>. 1.34 (0.86, 1.92), <i>P</i> = 0.045]. The prevalence of maternal composite outcomes (66.08% <i>vs</i>. 58.90%, <i>p</i> = 0.09) and fetal loss (10.49% <i>vs</i>. 5.78%, <i>P</i> = 0.02) was greater among women with 2.5 &lt; TSH ≤ 4.08 mIU/L than among those with 0.23 &lt; TSH ≤ 2.5 mIU/L. When the TSH concentration ranged from 0.23 to 2.5 mIU/L, the prevalence of fetal loss was greater in the TPOAb or TgAb positive group than in the antibody-negative group (8.33% <i>vs</i>. 5.43%, <i>P</i> = 0.04). Compared with TPOAb measruement alone, the predictive value of the TPOAb and TgAb combined assessment for maternal (AUC values: 0.509, 95% CI = 0.485 ~ 0.532) and fetal (AUC values: 0.512, 95% CI = 0.458 ~ 0.565) adverse outcomes was not higher.</p> Conclusion <p>Under current treatment recommendations, the combined assessment of TPOAb and TgAb during pregnancy has limited predictive value for maternal–fetal adverse outcomes among euthyroid women compared with isolated TPOAb.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the predictive role of thyroglobulin antibodies combined with thyroid peroxidase antibodies on adverse pregnancy outcomes during early pregnancy

  • 期刊论文

  • 发表日期：

    2025年7月30日

查看全文
  • Peiheng Zhang,
  • Weijie Sun,
  • Jing Wang,
  • Yang Zhang,
  • Huixia Yang,
  • Ying Gao

摘要

Objective

The objective of this study was to explore whether combined assessment of TgAb and TPOAb perform a higher predictive value to adverse pregnancy outcomes than isolated TPOAb during early pregnancy.

Methods

This was a retrospective study of 4678 pregnant women receiving prenatal care at Peking University First Hospital from October 2017 to August 2018. Demographic and clinical data, including thyroid hormone levels, were retrieved from electronic medical records. The general information and incidence of adverse pregnancy outcomes were compared between different subgroups of thyroid function and antibody status.

Results

In total, 2673 women were enrolled. 6.70% (179/2673) and 8.27% (221/2673) of the pregnant women were TPOAb positive and TgAb positive, respectively. The median thyroid-stimulating hormone (TSH) level was higher in the TPOAb or TgAb positive group than in the antibody-negative group [1.40 (0.96, 2.01) vs. 1.34 (0.86, 1.92), P = 0.045]. The prevalence of maternal composite outcomes (66.08% vs. 58.90%, p = 0.09) and fetal loss (10.49% vs. 5.78%, P = 0.02) was greater among women with 2.5 < TSH ≤ 4.08 mIU/L than among those with 0.23 < TSH ≤ 2.5 mIU/L. When the TSH concentration ranged from 0.23 to 2.5 mIU/L, the prevalence of fetal loss was greater in the TPOAb or TgAb positive group than in the antibody-negative group (8.33% vs. 5.43%, P = 0.04). Compared with TPOAb measruement alone, the predictive value of the TPOAb and TgAb combined assessment for maternal (AUC values: 0.509, 95% CI = 0.485 ~ 0.532) and fetal (AUC values: 0.512, 95% CI = 0.458 ~ 0.565) adverse outcomes was not higher.

Conclusion

Under current treatment recommendations, the combined assessment of TPOAb and TgAb during pregnancy has limited predictive value for maternal–fetal adverse outcomes among euthyroid women compared with isolated TPOAb.